RESULT Act FDA Modernization
2025 · 2nd Quarter (Apr 1 - June 30)
ENDEAVOR BIOMEDICINES
Filed by AVIVA STRATEGIES (FKA MGB CONSULTING).
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 16, 2025
- Income
- $51,000.00
- Expenses
- Not reported
- Registrant
- AVIVA STRATEGIES (FKA MGB CONSULTING)
- Client
- ENDEAVOR BIOMEDICINES
- Filing UUID
- bbb895e0-122a-4450-8fd1-fb71692ae998
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.